Literature DB >> 27709566

Mutagenesis and Genome Engineering of Epstein-Barr Virus in Cultured Human Cells by CRISPR/Cas9.

Kit-San Yuen1, Chi-Ping Chan1, Kin-Hang Kok2, Dong-Yan Jin3.   

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 nuclease (Cas9) system is a powerful genome-editing tool for both chromosomal and extrachromosomal DNA. DNA viruses such as Epstein-Barr virus (EBV), which undergoes episomal replication in human cells, can be effectively edited by CRISPR/Cas9. We have demonstrated targeted editing of the EBV genome by CRISPR/Cas9 in several lines of EBV-infected cells. CRISPR/Cas9-based mutagenesis and genome engineering of EBV provides a new method for genetic analysis, which has some advantages over bacterial artificial chromosome-based recombineering. This approach might also prove useful in the cure of EBV infection. In this chapter, we use the knockout of the BART promoter as an example to detail the experimental procedures for construction of recombinant EBV in human cells.

Entities:  

Keywords:  Cure of Epstein–Barr virus infection; Episomal viral DNA genome; Epstein–Barr virus; Genetic analysis of Epstein–Barr virus; RNA-guided genome editing

Mesh:

Year:  2017        PMID: 27709566     DOI: 10.1007/978-1-4939-6472-7_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production.

Authors:  H M Abdullah Al Masud; Takahiro Watanabe; Masahiro Yoshida; Yoshitaka Sato; Fumi Goshima; Hiroshi Kimura; Takayuki Murata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 2.  A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.

Authors:  Anna Bellizzi; Nicholas Ahye; Gauthami Jalagadugula; Hassen S Wollebo
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-11       Impact factor: 4.147

Review 3.  CRISPR Editing Technology in Biological and Biomedical Investigation.

Authors:  Martyn K White; Rafal Kaminski; Won-Bin Young; Pamela C Roehm; Kamel Khalili
Journal:  J Cell Biochem       Date:  2017-07-04       Impact factor: 4.429

Review 4.  Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development.

Authors:  Man Teng; Yongxiu Yao; Venugopal Nair; Jun Luo
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 5.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

Review 6.  CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.

Authors:  Arinze Okoli; Malachy I Okeke; Morten Tryland; Ugo Moens
Journal:  Viruses       Date:  2018-01-22       Impact factor: 5.048

7.  Rescue of Recombinant Adenoviruses by CRISPR/Cas-Mediated in vivo Terminal Resolution.

Authors:  André Riedl; Julian Fischer; Hans-Gerhard Burgert; Zsolt Ruzsics
Journal:  Front Microbiol       Date:  2022-03-18       Impact factor: 5.640

Review 8.  Class 2 CRISPR/Cas: an expanding biotechnology toolbox for and beyond genome editing.

Authors:  Yuyi Tang; Yan Fu
Journal:  Cell Biosci       Date:  2018-11-12       Impact factor: 7.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.